Artificial intelligence has dominated investor attention for two years, but biotech revenue lines are also bending sharply higher. A small group of biotechs is building real commercial businesses around recently approved drugs, with growth profiles that stack up favorably against many AI darlings on a fundamentals basis. The three names below all reported Q4 2025 ... 3 Biotech Stocks to Watch for Respectable Growth Beyond AI
AI commentary is generated from public news feeds and is not investment advice.